Molecular pathogenesis of tuber formation in tuberous sclerosis complex

Journal of Child Neurology

Volumn 19, Issue 9, 2004, Pages 716-725

  Crino, Peter B ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAMARTIN; RIBOSOME PROTEIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE; TUBERIN;

BRAIN DEVELOPMENT; BRAIN TUMOR; CELL DEATH; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL TYPE; DYSPLASIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; GIANT CELL; HISTOPATHOLOGY; HUMAN; INTRACTABLE EPILEPSY; NERVE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUBEROUS SCLEROSIS;

EID: 8844224854     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738040190091301     Document Type: Review

References (57)

1. van Slegtenhorst M, de Hoogt R, Hermans C, et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-808.
2. Consortium ECTS: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-1315.
3. Sparagana SP, Roach ES: Tuberous sclerosis complex. Curr Opin Neurol 2000;13:115-119.
4. Bolton PF, Park RJ, Higgins JN, et al: Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002;125:1247-1255.
5. Koh S, Jayakar P, Dunoyer C, et al: Epilepsy surgery in children with tuberous sclerosis complex: Presurgical evaluation and outcome. Epilepsia 2000;41:1206-1213.
6. Richardson EP: Pathology of tuberous sclerosis. Ann N Y Acad Sci 1991;615:128-139.
7. Park SH, Pepkowitz SH, Kerfoot C, et al: Tuberous sclerosis in a 20-week gestation fetus: Immunohistochemical study. Acta Neuropathol (Berl) 1997;94:180-186.
8. Trombley IK, Mirra SS: Ultrastructure of tuberous sclerosis: Cortical tuber and subependymal tumor. Ann Neurol 1981;9:174-181.
9. Yamanouchi H, Jay V, Rutka JT, et al: Evidence of abnormal differentiation in giant cells of tuberous sclerosis. Pediatr Neurol 1997;17:49-53.
10. Huttenlocher PR, Heydemann PT: Fine structure of cortical tubers in tuberous sclerosis. Ann Neurol 1984;16:595-602.
11. Hirose Y, Scheithauer BW, Lopes MBS, et al: Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: An immunohistochemical. ultrastructural, and immunoelectron microscopic study. Acta Neuropathol 1995;90:387-399.
12. Lopes MBS, Altermatt HJ, Scheitauer BW, et al: Immunohistochemical characterization of subependymal giant cell astrocytomas. Acta Neuropathol 1996;91:368-375.
13. Crino PB, Dichter MA, Trojanowski JQ, Eberwine J: Embryonic neuronal markers in tuberous sclerosis: Single cell molecular pathology. Proc Nat Acad Sci U S A 1996;93:14152-14157.
14. Arai Y, Takashima S, Becker LE: CD44 expression in tuberous sclerosis. Pathobiology 2000;68:87-92.
15. White R, Hua Y, Lynch DR, et al: Differential transcription of neurotransmitter receptor subunits and uptake sites in giant cells and dysplastic neurons in cortical tubers. Ann Neurol 2001;49:67-78.
16. Lee A, Maldonado M, Baybis MS, et al: Markers of cellular proliferation are expressed in cortical tubers. Ann Neurol 2003; 53: 668-673.
17. Kyin R, Hua Y, Baybis M, et al: Differential cellular expression of neurotrophins in cortical tubers of the tuberous sclerosis complex. Am J Pathol 2001;159:1541-1554.
18. Guerreiro MM, Andermann F, Andermann E, et al: Surgical treatment of epilepsy in tuberous sclerosis: Strategies and results in 18 patients. Neurology 1998;51:1263-1269.
19. Wolf HK, Normann S, Green AJ, et al: Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions. Acta Neuropathol (Berl) 1997; 93:93-96.
20. Lippa CF, Pearson D, Smith TW. Cortical tubers demonstrate reduced immunoreactivity for synapsin I. Acta Neuropathol 1993; 85:449-451.
21. Plank TL, Yeung RS, Henske EP: Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998;58:4766-4770.
22. Lamb RF, Roy C, Diefenbach TJ, et al: The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000;2:281-287.
23. Geist RT, Gutmann DH: The tuberous sclerosis 2 gene is expressed at high levels in the cerebellum and developing spinal cord. Cell Growth Differ 1995;6:1477-1483.
24. Geist RT, Reddy AJ, Zhang J, Gutmann DH: Expression of the tuberous sclerosis 2 gene product, tuberin, in adult and developing nervous system tissues. Neurobiol Dis 1996;3:11-120.
25. Kerfoot C, Wienecke R, Menchine M, et al. Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesion of patients with tuberous sclerosis. Brain Pathol 1996;6:367-377.
26. Mizuguchi M, Kato M, Yamanouchi H, et al: Tuberin immunohistochemistry in brain, kidneys and heart with or without tuberous sclerosis. Acta Neuropathol (Berl) 1997;94:525-531.
27. Wienecke R, Maize J, Reed J, et al: Expression of the TSC2 product tuberin and its target Rap1 in non-nal human tissues. Am J Pathol 1997;150:43-50.
28. Wienecke R, Maize J, Shoarinejad F, et al: Co-localization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus. Oncogene 1996;13:913-923.
29. Soucek T, Pusch O, Wienecke R, et al: Role of the tuberous sclerosis gene-2 product in cell cycle control. J Biol Chem 1997;272:29301-293082.
30. Soucek T, Holzl G, Bernaschek G, Hengstschlager M: A role of the tuberous sclerosis gene-2 product during neuronal differentiation. Oncogene 1998;16:2197-2204.
31. Catania MG, Mischel PS, Vinters HV: Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B. J Neuropathol Exp Neurol 2001;60:711-723.
32. Crino PB, Henske EP: New developments in the neurobiology of the tuberous sclerosis complex. Neurology 1999;53:1384-1391.
33. Potter CJ, Huang H, Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 2001;105:357-368.
34. Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 2001;15:1383-1392.
35. van Slegtenhorst M, Nellist M, Nagelkerken B, et al: Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998;7:1053-1057.
36. Arrazola P, Hino O, Kobayashi T, et al: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002;4:699-704.
37. Kenerson HL, Aicher LD, True L, et al: Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-5650.
38. Schmelzle T, Hall MN, et al: TOR, a central controller of cell growth. Cell 2000;103:253-262.
39. McManus EJ, Alessi DR: TSC1-TSC2: A complex tale of PKB-mediated S6K regulation. Nat Cell Biol 2002;4:E214-E216.
40. Tee AR, Fingar DC, Manning BD, et al: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 2002;99:13571-13576.
41. Inoki K, Li Y, Zhu T, et al: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648-657.
42. Onda H, Crino PB, Zhang H, et al: Tsc2 null murine neuronal epithelial cells are a model for human tuber giant cells and show activation of an mTOR pathway. Mol Cell Neurosci 2002;21: 561-574.
43. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ: Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003;361: 1348-1349.
44. Green AJ, Smith M, Yates JR: Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994;6:193-196.
45. Henske E, Scheithauer B, Short M, et al: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996;59:400-406.
46. Henske E, Wessner L, Golden J, et al: Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 1997;151:1639-1647.
47. Niida Y, Stemmer-Rachamimov AO, Logrip M, et al: Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001;69:493-503.
48. Johnson MW, Emelin JK, Park SH: Co-localization of TSC1 and TSC2 gene products in tubers of patients with tuberous sclerosis. Brain Pathol 1999;9:45-54.
49. Kerfoot C, Wienecke R, Menchine M, et al: Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesion of patients with tuberous sclerosis. Brain Pathol 1996;6:367-377.
50. Mizuguchi M, Kato M, Yamanouchi H, et al: Tuberin immunohistochemistry in brain, kidneys and heart with or without tuberous sclerosis. Acta Neuropathol (Berl) 1997;94:525-531.
51. Han S, Santos TM, Puga A, et al: Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 2004;64: 812-816.
52. Dabora SL, Jozwiak S, Franz DN, et al: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80.
53. Roach ES, Gomez MR, Northrup H: Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J Child Neurol 1998;13:624-628.
54. Parent JM, Valentin VV, Lowenstein DH, et al: Prolonged seizures increase proliferating neuroblasts in the adult rat subventricular zone-olfactory bulb pathway. J Neurosci 2002;22:3174-3188.
55. Griffiths PD, Bolton P, Verity C: White matter abnormalities in tuberous sclerosis complex. Acta Radiol 1998;39:482-486.
56. Baron Y, Barkovich AJ: MR imaging of tuberous sclerosis in neonates and young infants. AJNR Am J Neuroradiol 1999;20: 907-916.
57. Maldonado M, Baybis M, Newman D, et al: Expression of ICAM-1 TNF-alpha, NFkappaB, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis 2003;14:279-290.